TAOK2

Across TCGA pan-cancer cohorts, TAOK2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TAOK2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TAOK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAOK2 expression acts as an unfavorable survival marker.

MESO, SKCM, and ESCA are the cancer types where TAOK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.082	0.414	.007	18	view →
SKCM	OS	Median	III,IV	0.223	0.728	<.001	15	view →
ESCA	DFS	Median	II,III,IV	0.184	0.525	.026	12	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	12	view →
HNSC	DFS	Median	All	0.347	0.630	.016	11	view →
COAD	DFS	Median	All	0.426	0.710	.003	11	view →
LIHC	DFS	Median	All	0.249	0.559	.024	9	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TAOK2–MESO (DFS)

Open the MESO breakdown →